Approval for the use of Eylea for MCV
The National Institute for Health and Care Excellence (NICE) has recommended Eylea (Aflibercept) as a suitable treatment for adults with visual impairments due to myopic choroidal neovascularisation (MCV).
Myopic choroidal neovascularisation is a rare complication of myopia (near-nearsightedness), which involves the growth of new blood vessels from the choroid.
Eylea is currently licensed in the UK as a treatment for wet age-related macular degeneration and some visual impairments due to diabetic macular oedema.
Michele Acton, CEO of Fight for Sight, said: “It’s welcome news that there is another treatment option approved by NICE for patients with MCV in England and Wales. Patients should have access to multiple treatment options. Patients should have access to multiple treatment options, especially as Eylea is approved for use in Scotland for patients with MCV.”